{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T21:07:48Z","timestamp":1771016868277,"version":"3.50.1"},"reference-count":65,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2009,4,24]],"date-time":"2009-04-24T00:00:00Z","timestamp":1240531200000},"content-version":"vor","delay-in-days":8698,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Scandinavian Journal of Haematology"],"published-print":{"date-parts":[[1985,7]]},"abstract":"<jats:p>It is difficult to compare the results of treatment obtained in different trials in myelomatosis because different sets of diagnostic criteria are used, and because the criteria by which patients are deemed eligible for entry vary. Thus the composition of different series of patients varies considerably. Furthermore, the outcome of treatment is recorded in different ways. Uniformity in the diagnostic categories entered would reduce the variance in survival between different trials: for example, trials in myelomatosis should exclude patients with monoclonal gammopathy of uncertain significance, non\u2010progressive or indolent myeloma, extramedullary plasmacytoma, and plasma\u2010cell leukaemia. The subdivision into simple prognostic groupings such as those proposed by the Medical Research Council is helpful in interpreting the survival patterns in different trials in which the proportions of patients in different prognostic groups are likely to vary. These groupings and other staging systems do not correlate with responsiveness to treatment. Rapid responders fare worse than slow responders, and this might provide a basis for a second randomisation to test whether a change in treatment could benefit the rapid responders.<\/jats:p>","DOI":"10.1111\/j.1600-0609.1985.tb00792.x","type":"journal-article","created":{"date-parts":[[2010,8,4]],"date-time":"2010-08-04T23:29:29Z","timestamp":1280964569000},"page":"10-19","source":"Crossref","is-referenced-by-count":18,"title":["Classification and prognostic variables in myelomatosis"],"prefix":"10.1111","volume":"35","author":[{"given":"Ole Paaske","family":"Hansen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David A. G.","family":"Galton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,4,24]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1948.10483269"},{"key":"e_1_2_1_3_2","first-page":"432","article-title":"Clinical course and survival in 16 patients with localized plas\u2010mocytoma","volume":"32","author":"Wollersheim HCH","year":"1984","journal-title":"Scand J Haematol"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.133.5.813"},{"key":"e_1_2_1_5_2","first-page":"29","article-title":"Multiple Myeloma: Review of 869 cases","volume":"50","author":"Kyle RA.","year":"1975","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/archinte.1975.00330010141018","article-title":"Clinical classification of plasma cell myeloma","volume":"135","author":"Conklin R.","year":"1975","journal-title":"Arch Intern Med"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198006123022405"},{"key":"e_1_2_1_8_2","first-page":"145","article-title":"Proposed guidelines for protocol studies. II. Plasma cell myeloma","volume":"4","author":"Committee of the Chronic Leukemia\u2010Myeloma Task Force, National Cancer Institute","year":"1973","journal-title":"Cancer Chem-other Rep"},{"key":"e_1_2_1_9_2","unstructured":"DrivshomAa.Myelomatosis.Thesis. K\u00f8benhavn: Munksgaard 1965."},{"key":"e_1_2_1_10_2","first-page":"885","article-title":"Differentialdiagnostik vid monoklonal gam\u2010mapati","volume":"82","author":"Hallen J.","year":"1969","journal-title":"Nord Med"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0009-8981(71)90252-X"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.135.1.95"},{"key":"e_1_2_1_13_2","first-page":"239","article-title":"Plasma cell asynchrony in myeloma: correlation of light and electron microscopy","volume":"13","author":"Bernier GM","year":"1976","journal-title":"Semin Haematol"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01490510"},{"key":"e_1_2_1_15_2","unstructured":"BergsagelDE KyleR. BatailleR.Plasma cell neoplasms. In:HollanSR SzarsI. eds.Educational manual international congresses ISH\u2010ISBT Budapest1982;43\u20136."},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1977.tb02726.x"},{"key":"e_1_2_1_17_2","first-page":"123","article-title":"Report on the first myelomatosis trial","volume":"24","author":"Medical Reseach Council's working party for therapeutic trials in leukaemia","year":"1973","journal-title":"Br J Haematol"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1980.328"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1980.330"},{"key":"e_1_2_1_20_2","unstructured":"Medical Research Council's working party on leukaemia in adults.Personal communication."},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830130406"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V48.1.41.41"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI106327"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"e_1_2_1_25_2","first-page":"1","article-title":"Appreciation de la masse tumorale et de sa regression sous traitement dans le myeloma multiple des os","volume":"45","author":"Bataille R.","year":"1978","journal-title":"Rev Rheuma-tol"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1979.tb01124.x"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood.V55.6.1011.1011","article-title":"A new improved clinical staging system for multiple myeloma based on analysis of 123 treated patients","volume":"55","author":"Merlini G.","year":"1980","journal-title":"Blood"},{"key":"e_1_2_1_28_2","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1182\/blood.V55.3.364.364","article-title":"Pretreatment tumor mass, cell kinetics and prognosis in multiple myeloma","volume":"55","author":"Durie BGM","year":"1980","journal-title":"Blood"},{"key":"e_1_2_1_29_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood.V54.1.13.13","article-title":"Improved survival of increased\u2010risk myeloma patients on combined triple\u2010alhylating\u2010agent therapy: A study of the CALGB","volume":"54","author":"Harley JB","year":"1979","journal-title":"Blood"},{"key":"e_1_2_1_30_2","first-page":"243","article-title":"The prognosis of multiple myeloma","volume":"23","author":"Jansen J.","year":"1980","journal-title":"Neth J Med"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1984.tb02205.x"},{"key":"e_1_2_1_32_2","unstructured":"MerliniG. CastelliG. BettiniR. MalacridaV. DeFran\u2010cescoD.Staging of multiple myeloma response to chemotherapy and survival.Proc Intern Soc Haematol Congress XIX Budapest1982;179."},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1983.tb02851.x"},{"key":"e_1_2_1_34_2","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1182\/blood.V54.4.824.824","article-title":"Combination chemotherapy with intermittent 1\u20133\u2010bis (2\u2010chlorethyl) 1\u2010nitrosurea (BCNU), cyclophosphamide, and prednisone for multiple myeloma","volume":"54","author":"Cohen HJ","year":"1979","journal-title":"Blood"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.135.1.157"},{"key":"e_1_2_1_36_2","first-page":"751","article-title":"Management and prognosis of multiple myeloma","volume":"51","author":"Kyle RA","year":"1976","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_1_37_2","doi-asserted-by":"publisher","DOI":"10.1159\/000207722"},{"key":"e_1_2_1_38_2","first-page":"107","article-title":"Prognostic factors in multiple myeloma","volume":"14","author":"Kiang DT","year":"1973","journal-title":"Proc Ann Ass Cancer Res"},{"key":"e_1_2_1_39_2","first-page":"671","article-title":"Prognoserelevante klinische und morphologische klassifikation des multiplen myeloms","volume":"49","author":"Wutke K.","year":"1979","journal-title":"Arch Geschwulstforsch"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00406934"},{"key":"e_1_2_1_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.00361.x"},{"key":"e_1_2_1_42_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.5.1072.1072"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197510)36:4<1192::AID-CNCR2820360403>3.0.CO;2-I"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197910043011402"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(93)90002-M"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(93)90003-N"},{"key":"e_1_2_1_47_2","first-page":"311","article-title":"Etude comparee de deux classifications pronostiques du myelome et recherche d'une correlation entre la plasmocytose medullaire initiale et le pronostic","volume":"25","author":"Pesce A.","year":"1983","journal-title":"Nouv Rev Fr Hematol"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1983.tb01468.x"},{"key":"e_1_2_1_49_2","first-page":"107","article-title":"A comparison of two staging systems for multiple myeloma","volume":"23","author":"Vercelli D.","year":"1981","journal-title":"Nouv Rev Fr Hematol"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb03935.x"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19821101)50:9<1669::AID-CNCR2820500902>3.0.CO;2-N"},{"key":"e_1_2_1_52_2","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood.V63.3.639.639","article-title":"Comparison of two long\u2010term chemotherapeutic regimens, with or without agents to modify skeletal repair, in multiple myeloma","volume":"63","author":"Cohen HJ","year":"1984","journal-title":"Blood"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1159\/000206796"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1977.1"},{"key":"e_1_2_1_55_2","first-page":"510","article-title":"Serum beta\u20102\u2010microglobulin in myelomatosis: potential value in stratification and monotoring","volume":"39","author":"Norfolk D.","year":"1979","journal-title":"Br J Cancer"},{"key":"e_1_2_1_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-5379(93)90004-O"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1983.tb02158.x"},{"key":"e_1_2_1_58_2","doi-asserted-by":"crossref","DOI":"10.1111\/j.1600-0609.1985.tb00794.x","article-title":"Beta\u20102\u2010microglobulin. A valuable parameter of stage, prognosis and response to therapy in myelomatosis","author":"Bjerrum OW","year":"1985","journal-title":"Scand J Haematol"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.288.6428.1411"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1973.tb00073.x"},{"key":"e_1_2_1_61_2","first-page":"139","article-title":"Bone marrow percentages of plasma cells in the staging of monoclonal gammopathies","volume":"22","author":"Vercelli D.","year":"1980","journal-title":"Nouv Fr H\u00e9matol"},{"key":"e_1_2_1_62_2","doi-asserted-by":"publisher","DOI":"10.1136\/pgmj.47.552.635"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.135.1.46"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(67)90074-5"},{"key":"e_1_2_1_65_2","first-page":"39","article-title":"Prognostic factors in multiple myeloma treated with prednisolone and sequential melphalan and ifosfamide: MIP combination chemotherapy","volume":"36","author":"Adachi T.","year":"1982","journal-title":"Acta Med Okuyama"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00320493"}],"container-title":["Scandinavian Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.1985.tb00792.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.1985.tb00792.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T18:58:13Z","timestamp":1697828293000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.1985.tb00792.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,7]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1985,7]]}},"alternative-id":["10.1111\/j.1600-0609.1985.tb00792.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.1985.tb00792.x","archive":["Portico"],"relation":{},"ISSN":["0036-553X"],"issn-type":[{"value":"0036-553X","type":"print"}],"subject":[],"published":{"date-parts":[[1985,7]]}}}